Abstracts tagged "Economics"

Abstract Number: 98 • 2014 ACR/ARHP Annual Meeting
Costs of Musculoskeletal Diseases in the United States, 1996-2011: Population Growth, Population Aging, Health Care Utilization, or Prices?
Edward H. Yelin¹, Miriam G. Cisternas², Laura Trupin³ and Stuart Gansky⁴, ¹Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ²MGC Data Services, Carlsbad, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Preventive & Restorative Dental Sciences, University of California, San Francisco, San Francisco, CA
Background/Purpose: Medical care costs have been a major concern for public policy for a generation. Concern about costs of musculoskeletal conditions (MUSC) has been fueled…
Abstract Number: 2781 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Adding Etanercept Vs. Sulfasalazine and Hydroxychloroquine to Methotrexate Therapy: A Randomized Noninferiority Trial
Nick Bansback¹, Ciaran Phibbs², Huiying Sun³, James R. O'Dell⁴, Mary Brophy⁵, Edward C. Keystone⁶, Sarah Leatherman⁷, Ted R. Mikuls⁴ and Aslam H. Anis³, ¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ²Health Economics Resource Center (152), Palo Alto VA Health Care System, Menlo Park, CA, ³St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵VA Boston Heathcare System, Boston, MA, ⁶Medicine, University of Toronto, Toronto, ON, Canada, ⁷VA Boston Heatlhcare System, Boston, MA
Background/Purpose: To estimate the incremental cost-effectiveness of etanercept plus methotrexate versus a triple regimen of disease-modifying anti rheumatic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) over 24…
Abstract Number: 2235 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Long-Term Opioid Use in the Treatment of Knee Osteoarthritis in Older Patients with Multiple Comorbidities
Jeffrey N. Katz¹, Savannah Smith², Jamie E. Collins³, Joanne M. Jordan⁴, David J. Hunter⁵, Edward H. Yelin⁶, Lisa Suter⁷, A. David Paltiel⁸ and Elena Losina³, ¹Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ²Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁴University of North Carolina Dept of Epidemiology, Chapel Hill, NC, ⁵Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁶Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁷Medicine, Rheumatol, TAC S541, Yale University, New Haven, CT, ⁸Yale School of Public Health, New Haven, CT
Background/Purpose: Because older patients with osteoarthritis (OA) and multiple comorbidities face high risk of toxicity from nonselective non-steroidal antiinflammatory drugs (NSAIDs) and Cox-2 inhibitors, opiates…
Abstract Number: 2121 • 2014 ACR/ARHP Annual Meeting
Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease
Ghaith Mitri¹, Eric Wittbrodt¹, Robin Turpin¹, Beni Tidwell² and Kathy Schulman², ¹Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ²Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose Gout flare prevention relies heavily on urate-lowering therapies (ULT) such as allopurinol (ALP) and febuxostat (FBX) but clinical decision-making in patients with moderate to…
Abstract Number: 2125 • 2014 ACR/ARHP Annual Meeting
Burden of Illness in Refractory Gouty Arthritis: A One-Year Prospective Multinational, Observational Study
Louis Bessette¹, Frédéric Lioté², Carmen Moragues³, Rüdiger Moericke⁴, Zhang Zhiyi⁵, Alberto Ferreira⁶, Pascal Lecomte⁶, Sophia Kessabi⁶, Haijun Tian⁷ and Jasvinder A. Singh^8,9, ¹CHUL, Quebec, QC, Canada, ²Hôpital Lariboisière & University Paris Diderot, Paris, France, ³Hospital Platón, Barcelona, Italy, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵The First Affiliated Hospital of Haerbin Medical University, Haerbin, China, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Mayo Clinic, Rochester, MN, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Refractory gouty arthritis (RGA) is a condition characterized by appearance of recurrent flares and contraindication, intolerance, or lack of efficacy to first-line anti-inflammatory therapy…
Abstract Number: 2849 • 2013 ACR/ARHP Annual Meeting
Medication Adherence and Healthcare Costs Among Patients With Fibromyalgia: Combination Medication Versus Duloxetine, Pregabalin, and Milnacipran Initiators
Nicole Marlow¹, Kit Simpson², James Zoller² and E. Baron Short³, ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Healthcare Leadership and Management, Medical University of South Carolina, Charleston, SC, ³Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
Background/Purpose: The combined use of prescription drugs (Rx) with complementary mechanisms of action has been described for treating fibromyalgia (FM). We examined medication adherence and…
Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
P.H.P. de Jong¹, A.E.a.M. Weel², J.J. Luime³, P.J. Barendregt², A.H. Gerards⁴, P.A. van der Lubbe⁴, M.H. de Jager⁵, P.B. de Sonnaville⁶, D. van Zeben⁷, B.A. Grillet⁸ and J.M.W. Hazes³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁶Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁷Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁸Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…
Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Eiichi Tanaka¹, Eisuke Inoue², Yoko Shimizu³, Akiko Kobayashi², Naoki Sugimoto², Daisuke Hoshi², Kumi Shidara², Eri Sato³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…
Abstract Number: 992 • 2013 ACR/ARHP Annual Meeting
Promise Of Behavioral Economics: Delay Discounting and Physical Activity In Patients With Musculoskeletal Diseases
Elena Losina¹, Yan Dong¹, Stephanie Chen², Ran Schwarzkopf³, Laurel Donnell-Fink⁴, David Lerner² and Jeffrey N. Katz⁵, ¹Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Orthopedics and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Orthopedics, University of California Irvine Medical Center, Orange, CA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Despite strong evidence that physical activity (PA) is associated with better quality of life, less pain and better functional status in persons with musculoskeletal…
Abstract Number: 993 • 2013 ACR/ARHP Annual Meeting
An Analysis Of Healthcare Resource Utilization Among Patients Undergoing Total Knee Arthroplasty In The United Kingdom
Mireia Raluy¹, Michael Schoenfeld², Dimitra Lambrelli¹, Meng Wang³, Ning Wu⁴, Shih-Yin Chen⁴ and Russel Burge², ¹Health Economics, United BioSource Corporation, London, United Kingdom, ²Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, ³Economic Analysis and Solutions, United BioSource Corporation, London, United Kingdom, ⁴Economic Analysis and Solutions, United BioSource Corporation, Lexington, MA
Background/Purpose: Elective total knee arthroplasty (eTkA) is among the most commonly performed surgical procedures. The typical reasons for eTkA are pain and decreased quality of…
Abstract Number: 996 • 2013 ACR/ARHP Annual Meeting
Predictors and Modeling of Costs in Rheumatoid Arthritis
Jonas Eriksson¹, Thomas Frisell², Johan Askling³ and Martin Neovius¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Costs in RA are substantial with 2-3 times higher mean annual costs than in the general population, but with a skewed cost distribution.[1] As…
Abstract Number: 1003 • 2013 ACR/ARHP Annual Meeting
Measuring Economic Value of Morning Stiffness; Consistency Over 1 Year
Risto Tuominen, Public Health, University of Turku, Turku, Finland
Background/Purpose: Economic evaluation of health care activities requires often measuring clinical symptoms and their changes also in monetary terms. Patients with rheumatoid arthritis (RA) may…
Abstract Number: 1004 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Two Rituximab Based Therapeutic Regimens For Longstanding Rheumatoid Arthritis
Luca Quartuccio¹, Rossella Di Bidino², Matteo Ruggeri³, Domenico Biasi⁴, Franco Schiavon⁵, Leonardo Punzi⁶, Silvano Adami⁷, Americo Cicchetti³ and Salvatore De Vita⁸, ¹Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ²HTA Unit, “A.Gemelli” Teaching Hospital, Rome, Italy, ³Faculty of Economics, Catholic University of the Sacred Heart, Rome, Italy, ⁴Rheumatology Clinic, University of Verona, Verona, Italy, ⁵Rheumatology Clinic, University of Padova, Padova, Italy, ⁶University of Padova, Rheumatology Unit, Padova, Italy, ⁷Rheumatology Department, University of Verona, Verona, Italy, ⁸Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: socioeconomic costs of rheumatoid arthritis (RA) are very high. Biologic therapies with different biologic targets are now available for moderate to severe RA, and…
Abstract Number: 1008 • 2013 ACR/ARHP Annual Meeting
Longitudinal Analysis Of Direct Medical Costs For Systemic Sclerosis Patients: A Population-Based Study
Natalie McCormick¹, Carlo A. Marra², Eric C. Sayre³ and J. Antonio Avina-Zubieta⁴, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: Patients with systemic sclerosis (SSc) have considerable morbidity which may be associated with high health resource utilization. Studies on health use and costs are…
Abstract Number: 827 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness and Cost-Utility Of a One-Year Coaching Program For Healthy Physical Activity In Rheumatoid Arthritis
Nina Brodin^1,2, Malin Lohela Karlsson³, Emma Swärdh² and Christina H. Opava⁴, ¹Department of Orthopaedics, Division of Physiotherapy, Dandeyd Hospital, Stockholm, Sweden, ²Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, SE 14183 Huddinge, Sweden, ³Institute of Environmental Medicine (IMM), Intervention and Implementation Research Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Neurobiology, Care Sciences and Society, Division of Physical Therapy, Karolinska Institutet, Huddinge, Sweden
Background/Purpose: Economic evaluations of interventions, as a complement to the effect evaluation, intend to inform decision makers about whether an intervention provides good value for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].